

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 December 21; 23(47): 8263-8438



### REVIEW

- 8263 Clinical epidemiology and disease burden of nonalcoholic fatty liver disease  
*Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A*

### MINIREVIEWS

- 8277 Obese children with fatty liver: Between reality and disease mongering  
*Ranucci G, Spagnuolo MI, Iorio R*
- 8283 Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities  
*Lippi G, Sanchis-Gomar F*

### ORIGINAL ARTICLE

#### Basic Study

- 8291 Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing  
*Youssef O, Sarhadi V, Ehsan H, Böhling T, Carpelan-Holmström M, Koskensalo S, Puolakkainen P, Kokkola A, Knuutila S*
- 8300 Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease  
*Senhaji N, Nadifi S, Zaid Y, Serrano A, Rodriguez DAL, Serbati N, Karkouri M, Badre W, Martín J*
- 8308 Effects of initiating time and dosage of *Panax notoginseng* on mucosal microvascular injury in experimental colitis  
*Wang SY, Tao P, Hu HY, Yuan JY, Zhao L, Sun BY, Zhang WJ, Lin J*
- 8321 Fructo-oligosaccharide intensifies visceral hypersensitivity and intestinal inflammation in a stress-induced irritable bowel syndrome mouse model  
*Chen BR, Du LJ, He HQ, Kim JJ, Zhao Y, Zhang YW, Luo L, Dai N*
- 8334 Morin enhances hepatic Nrf2 expression in a liver fibrosis rat model  
*Sang L, Wang XM, Xu DY, Sang LX, Han Y, Jiang LY*
- 8345 Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer  
*Yang F, Liu DY, Guo JT, Ge N, Zhu P, Liu X, Wang S, Wang GX, Sun SY*

#### Case Control Study

- 8355 Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity  
*Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H*

**Retrospective Study**

- 8367 Association between white opaque substance under magnifying colonoscopy and lipid droplets in colorectal epithelial neoplasms  
*Kawasaki K, Eizuka M, Nakamura S, Endo M, Yanai S, Akasaka R, Toya Y, Fujita Y, Uesugi N, Ishida K, Sugai T, Matsumoto T*
- 8376 Nomogram based on tumor-associated neutrophil-to-lymphocyte ratio to predict survival of patients with gastric neuroendocrine neoplasms  
*Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, Wang JB, Chen QY, Lin M, Tu RH, Huang CM*
- 8387 Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis  
*Xiang JX, Hu LS, Liu P, Tian BY, Su Q, Ji YC, Zhang XF, Liu XM, Wu Z, Lv Y*

**Clinical Trials Study**

- 8395 First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease  
*Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group*

**Observational Study**

- 8405 Rate of adverse events of gastroduodenal snare polypectomy for non-flat polyp is low: A prospective and multicenter study  
*Córdova H, Argüello L, Loras C, Naranjo Rodríguez A, Riu Pons F, Gornals JB, Nicolás-Pérez D, Andújar Murcia X, Hernández L, Santolaria S, Leal C, Pons C, Pérez-Cuadrado-Robles E, García-Bosch O, Papo Berger M, Ulla Rocha JL, Sánchez-Montes C, Fernández-Esparrach G*

**META-ANALYSIS**

- 8415 Chronic kidney disease severely deteriorates the outcome of gastrointestinal bleeding: A meta-analysis  
*Hägendorn R, Farkas N, Vincze Á, Gyöngyi Z, Csupor D, Bajor J, Erőss B, Csécsi P, Vasas A, Szakács Z, Szapáry L, Hegyi P, Mikó A*

**CASE REPORT**

- 8426 Disabling portosystemic encephalopathy in a non-cirrhotic patient: Successful endovascular treatment of a giant inferior mesenteric-caval shunt *via* the left internal iliac vein  
*de Martinis L, Groppelli G, Corti R, Moramarco LP, Quaretti P, De Cata P, Rotondi M, Chiovato L*
- 8432 Wernicke encephalopathy in a patient after liver transplantation: A case report  
*Xie B, Si ZZ, Tang WT, Qi HZ, Li T*

**LETTERS TO THE EDITOR**

- 8437 Silymarin: An option to treat non-alcoholic fatty liver disease  
*Colica C, Boccuto L, Abenavoli L*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Yoshihisa Takahashi, MD, Associate Professor, Department of Pathology, Teikyo University School of Medicine, Tokyo 173-8605, Japan

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

**FLYLEAF**

**I-IX** Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Yan Huang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Ze-Mao Gong*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Gastroenterology*

**ISSN**  
 ISSN 1007-9327 (print)  
 ISSN 2219-2840 (online)

**LAUNCH DATE**  
 October 1, 1995

**FREQUENCY**  
 Weekly

**EDITORS-IN-CHIEF**  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

**EDITORIAL BOARD MEMBERS**  
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Inc  
 7901 Stoneridge Drive, Suite 501,  
 Pleasanton, CA 94588, USA  
 Telephone: +1-925-2238242  
 Fax: +1-925-2238243  
 E-mail: [bpoffice@wjgnet.com](mailto:bpoffice@wjgnet.com)  
 Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

**PUBLICATION DATE**  
 December 21, 2017

**COPYRIGHT**  
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**  
<http://www.f6publishing.com>

## Clinical Trials Study

**First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease**

Chih-Ming Liang, Ming-Te Kuo, Pin-I Hsu, Chao-Hung Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Hsing-Ming Wang, Chih-Chien Yao, Cheng-En Tsai, Yao-Kuang Wang, Jiunn-Wei Wang, Chih-Fang Huang, Deng-Chyang Wu, Seng-Kee Chuah; Taiwan Acid-Related Disease Study Group

Chih-Ming Liang, Ming-Te Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Hsing-Ming Wang, Chih-Chien Yao, Cheng-En Tsai, Seng-Kee Chuah, Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan

Pin-I Hsu, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, National Yang-Ming University, Kaohsiung 833, Taiwan

Chao-Hung Kuo, Yao-Kuang Wang, Jiunn-Wei Wang, Deng-Chyang Wu, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung 833, Taiwan

Chih-Fang Huang, Division of Family Physicians, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan

ORCID numbers: Chih-Ming Liang (0000-0002-6614-5937); Ming-Te Kuo ((0000-0001-9223-318X); Pin-I Hsu (0000-0003-3905-4674); Chao-Hung Kuo (0000-0003-1847-395X); Wei-Chen Tai (0000-0002-8026-1408); Shih-Cheng Yang (0000-0002-8288-8845); Keng-Liang Wu (0000-0002-8703-6625); Hsing-Ming Wang (0000-0002-2599-6495); Chih-Chien Yao (0000-0002-4868-200X); Cheng-En Tsai (0000-0001-9840-4051); Yao-Kuang Wang (0000-0002-5536-7542); Jiunn-Wei Wang (0000-0003-2534-438X); Chih-Fang Huang (0000-0002-5900-292X); Deng-Chyang Wu (0000-0003-3742-0634); Seng-Kee Chuah (0000-0002-8934-3223).

**Author contributions:** Liang CM and Kuo MT contributed equally to this work; Chuah SK contributed to the research design and critical revision of the manuscript for important intellectual content; Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC

and Chuah SK performed the research; Liang CM and Kuo MT analyzed the data and wrote the manuscript; all authors approved the final version of the manuscript.

**Supported by** Research Foundation of Chang Gung Memorial Hospital, No. CMRPG8D1441.

**Institutional review board statement:** The study was reviewed and approved by the Chang Gung Memorial Hospital institutional review board.

**Clinical trial registration statement:** ClinicalTrials.gov number: NCT03128736.

**Informed consent statement:** The data collection in this study is based on reviewing computerized medical charts. Informed consent was obtained from all patients in the study.

**Conflict-of-interest statement:** None of the authors have a conflict of interest related to the manuscript.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Seng-Kee Chuah, MD, Chief Doctor, Professor, Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital

and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao-Sung District, Kaohsiung 833, Taiwan. [chuahsk@cgmh.org.tw](mailto:chuahsk@cgmh.org.tw)  
Telephone: +886-7-7317123-2360  
Fax: +886-7-7322402

Received: July 28, 2017  
Peer-review started: July 28, 2017  
First decision: August 30, 2017  
Revised: September 19, 2017  
Accepted: September 26, 2017  
Article in press: September 26, 2017  
Published online: December 21, 2017

## Abstract

### AIM

To compare the one-week clinical effects of single doses of dexlansoprazole and esomeprazole on grades A and B erosive esophagitis.

### METHODS

We enrolled 175 adult patients with gastroesophageal reflux disease (GERD). The patients were randomized in a 1:1 ratio into two sequence groups to define the order in which they received single doses of dexlansoprazole ( $n = 88$ ) and esomeprazole ( $n = 87$ ) for an intention-to-treat analysis. The primary end-points were the complete symptom resolution (CSR) rates at days 1, 3, and 7 after drug administration.

### RESULTS

Thirteen patients were lost to follow-up, resulting in 81 patients in each group for the per-protocol analysis. The CSRs for both groups were similar at days 1, 3 and 7. In the subgroup analysis, the female patients achieved higher CSRs in the dexlansoprazole group than in the esomeprazole group at day 3 (38.3% *vs* 18.4%,  $P = 0.046$ ). An increasing trend toward a higher CSR was observed in the dexlansoprazole group at day 7 (55.3% *vs* 36.8%,  $P = 0.09$ ). In the esomeprazole group, female sex was a negative predictive factor for CSR on post-administration day 1 [OR =  $-1.249 \pm 0.543$ ; 95%CI: 0.287 (0.099-0.832),  $P = 0.022$ ] and day 3 [OR =  $-1.254 \pm 0.519$ ; 95%CI: 0.285 (0.103-0.789),  $P = 0.016$ ]. Patients with spicy food eating habits achieved lower CSRs on day 1 [37.3% *vs* 21.4%, OR =  $-0.969 \pm 0.438$ ; 95%CI: 0.380 (0.161-0.896),  $P = 0.027$ ].

### CONCLUSION

The overall CSR for GERD patients was similar at days 1-7 for both the dexlansoprazole and esomeprazole groups, although a higher incidence of CSR was observed on day 3 in female patients who received a single dose of dexlansoprazole.

**Key words:** Dexlansoprazole; Esomeprazole; One-week response; Complete symptom resolution rate; Gastroesophageal reflux disease

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** No existing report has investigated the short-term clinical effects of dexlansoprazole 60 mg *vs* esomeprazole 40 mg. This study compared the one-week clinical effects of a single dose of the two drugs for grades A and B erosive esophagitis. We enrolled 175 adult patients with gastroesophageal reflux disease (GERD) and randomized them in a 1:1 ratio into a dexlansoprazole ( $n = 88$ ) or esomeprazole group ( $n = 87$ ) for an intention-to-treat analysis (ITT). The primary end-points were the complete symptom resolution (CSR) rates at days 1, 3, and 7. The CSRs for both groups were similar at days 1, 3 and 7. In the subgroup analysis, female patients achieved higher CSRs in the dexlansoprazole group than in the esomeprazole group at day 3 (38.3% *vs* 18.4%,  $P = 0.046$ ). In the esomeprazole group, female sex was a negative predictive factor for CSR at post-dose day 1 [OR =  $-1.249 \pm 0.543$ ; 95%CI: 0.287 (0.099-0.832),  $P = 0.022$ ] and day 3 [OR =  $-1.254 \pm 0.519$ ; 95%CI: 0.285 (0.103-0.789),  $P = 0.016$ ]. This pilot study suggested that the overall CSR rates for GERD patients were similar at days 1 through 7 for both the dexlansoprazole and esomeprazole groups, although a higher CSR was observed at day 3 in female patients who received a single dose of dexlansoprazole.

Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. *World J Gastroenterol* 2017; 23(47): 8395-8404 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i47/8395.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i47.8395>

## INTRODUCTION

Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder worldwide. GERD continues to increase in incidence with the aging population and the obesity epidemic<sup>[1,2]</sup>. Based on the Montreal definition, GERD is diagnosed when the reflux of stomach contents causes troublesome symptoms<sup>[3]</sup>, such as heartburn and regurgitation, as well as other atypical or extraesophageal symptoms, such as chest pain, asthma, voice hoarseness, and sleep disturbance<sup>[4]</sup>. Proton pump inhibitors (PPIs) are widely recognized as superior to other antisecretory therapies, including histamine-2 receptor antagonists (H<sub>2</sub>RA), and thus play a critical role in pharmacological therapy for the treatment of GERD<sup>[5]</sup>. Although PPIs represent the mainstay of treatment for healing erosive esophagitis,

symptom relief, and preventing complications, several studies have shown that up to 40% of GERD patients report either a partial or a complete lack of response of their symptoms after taking a standard once-daily PPI dose<sup>[6-8]</sup>.

A study comparing the pharmacokinetic effects of different PPIs 12-24 h post-dose showed that the mean percentage of time with a pH > 4 and the average of the pH mean were greater for dexlansoprazole than for esomeprazole (60% vs 42%,  $P < 0.001$  and pH 4.5 vs 3.5,  $P < 0.001$ ). However, this study did not report the clinical effects after the use of tablets<sup>[9]</sup>. Rapid onset PPIs for fast symptom relief is an unmet need in GERD treatment. To date, no reports have investigated the differences in short-term clinical effects and timing to symptom relief of GERD between dexlansoprazole 60 mg and esomeprazole 40 mg. Therefore, we conducted a randomized, controlled, open-label study to compare the 7-d clinical effects of single doses of dexlansoprazole (60 mg) and esomeprazole (40 mg) in patients with Los Angeles (LA) grades A and B erosive esophagitis.


## MATERIALS AND METHODS

### Ethics statement

This study was funded by the Research Foundation of the Chang Gung Memorial Hospital, Taiwan (CMRPG8D1441). This open-labeled trial was conducted at Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Medical University Hospital, and Kaohsiung Veterans General Hospital in Taiwan. The study protocol was approved by the Ethics Committees of the above three hospitals. All patients provided written informed consent prior to participation. This clinical trial has been registered in a publicly accessible registry (ClinicalTrials.gov number: NCT03128736).

### Study population

We invited 243 eligible outpatients to join our study. The outpatients were at least 18 years old, presented with clinical symptoms of acid regurgitation, heartburn, and a feeling of acidity in the stomach<sup>[10]</sup>, and had endoscopy-confirmed LA grade A or B erosive esophagitis<sup>[11,12]</sup>. We enrolled a total of 175 patients using strict inclusion criteria. The exclusion criteria included (1) those who had been taking antisecretory agents, such as PPIs and H<sub>2</sub>RA, within 2 wk prior to the endoscopy; (2) those who had coexistence of a peptic ulcer or gastrointestinal malignancies, and were pregnant; (3) those who had coexistence of a serious concomitant illness (*e.g.*, decompensated liver cirrhosis and uremia); (4) those who underwent previous gastric surgery; (5) those who were allergic to dexlansoprazole or esomeprazole; and (6) those who had a symptom score less than 12 on a validated



**Figure 1 Schematic flowchart of the study design.** ITT: Intention-to-treat; PP: Per protocol.

questionnaire (Chinese GERDQ)<sup>[10]</sup>.

### Study protocol

Figure 1 shows the schematic flowchart of the study design. Eligible patients were randomly assigned to receive either dexlansoprazole 60 mg q.d. or esomeprazole 40 mg q.d. for 8 wk as an initial treatment. Randomization was conducted using a computer-generated list of random numbers in a 1:1 ratio into two sequence groups that defined the order in which the patients received a single dose of dexlansoprazole or esomeprazole for an intention-to-treat analysis. An independent staff member assigned the treatments according to consecutive numbers kept in sealed envelopes. Written informed consent was obtained from each patient.

Each patient completed diary cards during the study period. Complete symptom resolution (CSR) was defined as no reflux symptoms leading to troublesome feelings in the 7 d of initial treatment. The patients were asked to complete the Chinese GERDQ upon recruitment<sup>[10]</sup>. The selected symptoms that best accounted for the differences between the

patients with GERD and the controls included acid regurgitation, heartburn, and a feeling of acidity in the stomach. The severity and frequency of symptoms in the questionnaire were graded on a five-point Likert scale as follows: (1) (none: no symptoms/none in the last month); (2) (mild: symptoms could be easily ignored/less than once per month); (3) (moderate: awareness of symptoms but easily tolerated/ $\geq$  once per month); (4) (severe: symptoms sufficient to interfere with normal activities/ $\geq$  once per week); and (5) (incapacitating: incapacitating symptoms with an inability to perform daily activities or requiring a day off work/ $\geq$  once daily)<sup>[10]</sup>. Blood samples were collected to measure the fasting blood sugar, serum cholesterol, and triglyceride levels. In addition, the body mass index (BMI) was calculated. Upon initial endoscopy, specimens taken from the greater curvature within 5 cm from the pylorus and from the greater curvature of the middle body were subjected to a microscopic examination for *Helicobacter pylori* (*H. pylori*) using a hematoxylin and eosin stain. No eradication therapy was administered during the study period.

#### Patient demographic data and follow-up

A complete medical history and demographic data were obtained from each patient. The collected variables included age (< 60 or  $\geq$  60 years), sex, history of smoking, history of alcohol consumption (< 80 g/d or  $\geq$  80 g/d), coffee ingestion (< 1 cup/d or  $\geq$  1 cup/d), tea ingestion (< 1 cup/d or  $\geq$  1 cup/d), coexistence of a systemic disease (yes or no), severity of erosive esophagitis, and BMI. A gastric biopsy for histology and an *H. pylori* examination were also performed. The patients returned to the clinics for drug refills and evaluation of reflux symptoms after one week. Adverse events were prospectively evaluated. The adverse events were assessed according to a 4-point scale system as follows: none; mild (discomfort, annoying but not interfering with daily work); moderate (discomfort sufficient to interfere with daily work); and severe (discomfort resulting in discontinuation of PPI therapy). Compliance was checked by counting the unused medication at the completion of 7 d of treatment.

#### End points

CSR was defined as no reflux symptoms sufficient to impair the quality of life before the end of the initial treatment phase. The main outcome measures were the CSR rates at days 1, 3 and 7 of the initial treatment period. All patients who started esomeprazole or dexlansoprazole as their initial treatment were included in the intent-to-treat (ITT) analysis. Patients with poor drug compliance were excluded from the per-protocol (PP) analysis. Poor compliance was defined as taking less than 80% of the total medication during the initial

treatment phase.

#### Statistical analysis

According to the observations in this study, the CSR rate after a once-daily PPI therapy was approximately 50% at day 7. Assuming that the two types of PPIs provided similar effects on the CSR rates with a standard deviation of less than 10%<sup>[13]</sup>, we estimated that we required at least 196 patients in each treatment group to demonstrate a 10% absolute difference in the CSR with a type I error of 0.05 and a statistical power of 80% and assuming a 10% loss to follow-up. As a consequence of not achieving the target number, our study was a pilot study.

In this pilot study, the  $\chi^2$  test with or without Yates correction for continuity and Fisher's exact test were used when appropriate to compare the rates of CSR, symptom relapse, and esophagitis relapse between the groups. The mean reflux symptom scores between groups were compared using the Wilcoxon rank sum test. All statistical analyses were performed using the SPSS program (version 10.1, Chicago, IL, United States). A *P* value less than 0.05 was considered significant.

## RESULTS

From April 2014 to March 2016, two hundred and forty-three eligible symptomatic patients who had endoscopy-confirmed Los Angeles grade A or B erosive esophagitis were assessed. A total of 175 of these patients were recruited for randomization after excluding 68 patients who refused enrollment (*n* = 40), cancer patients (*n* = 19), and patients with advanced liver disease (*n* = 3), end-stage renal disease (*n* = 4), and coronary heart disease (*n* = 2). A total of 88 patients received the dexlansoprazole treatment, and 87 patients received the esomeprazole treatment. A total of 13 patients were lost during the follow-up period (seven in the dexlansoprazole group and 6 in the esomeprazole group) (Figure 1). The baseline characteristics of the two groups were similar in age, sex, diet habits, body mass index, and symptom scores (GERDQ) (Table 1). At days 1, 3, and 7 post-dose, the CSR rates for the dexlansoprazole vs esomeprazole groups were 25.9% vs 28.4% (*P* = 0.724), 33.3% vs 32.1% (*P* = 0.867), and 51.9% vs 48.1% (*P* = 0.637), respectively. The symptoms and frequencies of nighttime reflux were similar in both groups (Table 2). In the subgroup analysis based on sex, females had higher CSR rates in the dexlansoprazole group at day 3 (38.3% vs 18.4%, *P* = 0.046), and an increasing trend was observed at day 7 (55.3% vs 36.8%, *P* = 0.09) (Table 3). However, no significant differences were observed in the subgroup analyses based on age and body weight. After splitting

**Table 1** Baseline characteristics of the patients [*n* = 81, *n* (%)]

Variables	Dexlansoprazole	Esomeprazole	<i>P</i> value
Age (mean ± SD, yr)	50.6 ± 13.3	49.9 ± 12.8	0.985
Male sex	34 (42.0)	43 (53.1)	0.137
Smoking	12 (14.8)	9 (11.1)	0.483
Alcohol use	22 (27.2)	22 (27.2)	1.000
Ingestion of coffee	44 (54.3)	36 (44.4)	0.209
Ingestion of tea	58 (71.6)	49 (60.5)	0.230
Betel nut	4 (4.9)	1 (1.2)	0.173
Spicy food	52 (64.2)	51 (63.0)	0.870
Sweet food	72 (88.9)	75 (92.6)	0.416
Body mass index	25.4 ± 4.8	24.9 ± 4.4	0.420
Waist girth	88.8 ± 12.2	88.7 ± 11.4	0.361
Metabolic syndrome	36 (44.4)	38 (46.9)	0.950
Atypical symptoms			
Chest pain	38 (46.9)	39 (48.1)	0.588
Dysphagia	20 (24.7)	22 (27.2)	0.557
Regurgitation of food	29 (35.8)	31 (38.3)	0.561
Nausea	26 (32.1)	23 (28.4)	0.544
Hiccup	37 (45.7)	44 (54.3)	0.300
Foreign body sensation (throat)	48 (59.3)	40 (49.4)	0.301
Foreign body sensation (chest)	16 (19.8)	16 (19.8)	0.604
Hoarseness	28 (34.6)	28 (34.6)	0.604
Throat cleaning	44 (54.3)	44 (54.3)	0.602
Cough	38 (46.9)	34 (42.0)	0.516
Sore throat	20 (24.7)	20 (24.7)	0.604
Dry mouth	54 (66.7)	52 (64.2)	0.590
Bad breath	29 (35.8)	30 (37.0)	0.590
Epigastric pain	36 (44.4)	45 (55.6)	0.197
Epigastric fullness	65 (80.2)	54 (66.7)	0.111
Insomnia	36 (44.4)	28 (34.6)	0.199
Sinusitis	7 (8.6)	14 (17.3)	0.102
Otitis media	5 (6.2)	5 (6.2)	1.000
Sugar	97.4 ± 12.5	97.0 ± 12.8	0.604
Cholesterol	205.3 ± 36.7	207.7 ± 35.4	0.971
Triglyceride	121.9 ± 57.2	113.7 ± 64.7	0.284
HDL	54.7 ± 18.2	55.3 ± 14.4	0.866
LDL	127.0 ± 32.7	127.5 ± 32.8	0.942
<i>H. pylori</i> infection			
Previous history - no	10 (12.3)	15 (18.5)	0.553
Current infection - no	10 (12.3)	12 (14.8)	0.703
Endoscopic findings			
Hiatal hernia	10 (12.3)	15 (18.5)	0.347
GEFV (grade 3 or 4)	7 (8.6)	8 (9.9)	0.521
Esophagitis grade B	15 (18.5)	13 (16.0)	0.678

HDL: High-density lipoprotein; LDL: low-density lipoprotein; *H. pylori*: *Helicobacter pylori*; GEFV: Gastroesophageal flap valve.

the data from the two PPI groups in the multivariate analysis, no dependent factor for CSR was found in the dexlansoprazole group (Table 4). In the esomeprazole group, female sex was a negative predictive factor for CSR at post-dose days 1 [OR = -1.249 ± 0.543; 95%CI: 0.287 (0.099-0.832), *P* = 0.022] and 3 [OR = -1.254 ± 0.519; 95%CI: 0.285 (0.103-0.789), *P* = 0.016]. In addition, patients with a habit of consuming spicy foods had lower CSR rates (37.3% vs 21.4%) on day 1 after the multivariate analysis [OR = -0.969 ± 0.438; 95%CI: 0.380 (0.161-0.896), *P* = 0.027] (Table 5). No dependent factor was found on days 3 and 7.

## DISCUSSION

We conducted a randomized, controlled, open-label

study to compare the 7-d clinical effects of single doses of dexlansoprazole 60 mg and esomeprazole 40 mg for GERD patients. We observed that the overall CSR rates for GERD patients were similar at days 1 through 7 of treatment for both the dexlansoprazole and esomeprazole groups. However, in our subgroup analysis based on sex, we observed that females had higher CSR rates in the dexlansoprazole group at day 3 (38.3% vs 18.4%, *P* = 0.046), and an increasing trend was observed at day 7 (55.3% vs 36.8%, *P* = 0.09). The logistic regression analysis showed that female sex was a negative predictive factor for CSR on post-dose days 1 [OR = -1.249 ± 0.543; 95%CI: 0.287 (0.099-0.832), *P* = 0.022] and 3 [OR = -1.254 ± 0.519; 95%CI: 0.285 (0.103-0.789), *P* = 0.016] in the esomeprazole group. We also found

**Table 2** Comparison of the complete symptom resolution rates and night-time breakthrough heartburn between dexlansoprazole and esomeprazole over one week [ $n = 81$ ,  $n$  (%)]

Variables	Dexlansoprazole	Esomeprazole	<i>P</i> value
CSR Day 1	21 (25.9)	23 (28.4)	0.724
CSR Day 3	27 (33.3)	26 (32.1)	0.867
CSR Day 7	42 (51.9)	39 (48.1)	0.637
Night reflux	45 (76.3)	40 (74.1)	0.787
Night heart burn	20 (33.9)	18 (33.3)	0.949
Night acid reflux	20 (33.9)	19 (35.2)	0.886
Frequency of night symptoms	2.7 ± 2.0	2.7 ± 2.4	0.343

CSR: Complete symptom resolution.

**Table 3** Comparison of the complete symptom resolution rates between dexlansoprazole and esomeprazole over one week (Subgroup analysis by gender)  $n$  (%)

Time	Gender	Dexlansoprazole	Esomeprazole	<i>P</i> value
CSR Day 1	Female	13 (27.7)	6 (15.8)	0.192
	Male	8 (23.5)	17 (39.5)	0.136
CSR Day 3	Female	18 (38.3)	7 (18.4)	0.046
	Male	9 (26.5)	19 (44.2)	0.109
CSR Day 7	Female	26 (55.3)	14 (36.8)	0.090
	Male	16 (47.1)	25 (58.1)	0.333

CSR: Complete symptom resolution.

that patients with the habit of eating spicy foods had lower CSR rates (37.3% vs 21.4%) on day 1 after the multivariate analysis [OR = -0.969 ± 0.438; 95%CI: 0.380 (0.161-0.896),  $P = 0.027$ ].

Both dexlansoprazole and esomeprazole are potent PPIs for gastric acid suppression with excellent symptom relief for patients with GERD<sup>[14-19]</sup>. The advantage of dexlansoprazole MR (Takeda Pharmaceuticals, Osaka, Japan) is that it employs a novel approach by which its dual delayed-release (DDR) formulation prolongs the plasma concentration and ultimately extends the duration of acid suppression<sup>[14]</sup>, thereby offering a twice-daily dosing effect in a one-time dose. Metz *et al*<sup>[15]</sup> found that patients who received a 60-mg dose of dexlansoprazole MR satisfactorily controlled heartburn (median of 91%-96% for 24-h heartburn-free days and 96%-99% for heartburn-free nights). Moreover, Sharma *et al*<sup>[16]</sup> reported that 92%-95% of patients were healed using dexlansoprazole MR for 8 wk. Conversely, esomeprazole (40 mg) is a delayed-release formulation with single-release characteristics that produces maximum plasma concentrations at approximately 1.6 h post-dose. Approximately 73%-75% heartburn-free days and 85%-91% heartburn-free nights were observed in patients who received 40 mg of esomeprazole for 4 wk<sup>[17-19]</sup>. In addition, esomeprazole at 40 mg/d also achieved good healing rates (87%-94.1%) for erosive esophagitis after 8 wk of treatment<sup>[18-20]</sup>.

However, no direct head-to-head comparative

report has investigated the short-term clinical effects or timing to symptom relief of GERD between dexlansoprazole at 60 mg and esomeprazole at 40 mg. Wu *et al*<sup>[21]</sup> reported an indirect comparative study that revealed that the dexlansoprazole 30 mg dose was more effective than esomeprazole at the 20 mg or 40 mg dose (RR = 2.01, 95%CI: 1.15-3.51; RR = 2.17, 95%CI: 1.39-3.38, respectively) for patients with non-erosive esophagitis at 4 wk. However, no significant differences were found in the healing rates of erosive esophagitis. A one-day comparative pH study showed that dexlansoprazole had a higher mean percentage of time with a pH > 4 than esomeprazole (58% and 48%,  $P = 0.003$ ) at 0-24 h post-dose<sup>[9]</sup>. Unfortunately, differences in the clinical effects between these two PPIs were not mentioned.

In this study, we found that the symptoms and frequencies of nighttime reflux were similar between the dexlansoprazole and esomeprazole groups ( $P = 0.787$  and  $P = 0.343$ , respectively). At days 1, 3, and 7 post-dose, the CSR rates between the two groups were similar (25.9% vs 28.4%,  $P = 0.724$ , 33.3% vs 32.1%,  $P = 0.867$ , and 51.9% vs 48.1%,  $P = 0.637$ , respectively). Nevertheless, we also observed that female patients had higher CSR rates in the dexlansoprazole group ( $P = 0.046$ ) and an increasing trend for the effect on day 7 ( $P = 0.09$ ) when we performed the subgroup analysis based on sex. Remarkably, our logistic regression analysis showed that female sex was a negative predictive factor for CSR on post-dose days 1 [OR = -1.249 ± 0.543; 95%CI: 0.287 (0.099-0.832),  $P = 0.022$ ] and 3 [OR = -1.254 ± 0.519; 95%CI: 0.285 (0.103-0.789),  $P = 0.016$ ] in the esomeprazole group. These findings implied that esomeprazole at 40 mg required more time (3 d) than dexlansoprazole at 60 mg to attain CSR in females. Several possible mechanisms may underlie these observations. First, both esomeprazole and dexlansoprazole are extensively metabolized in the liver by oxidation, reduction, and subsequent conversion of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP)

**Table 4** Multivariate analysis of the clinical factors predictive of complete symptom resolution within one week based on dexlansoprazole and esomeprazole administration

Time	PPI	Clinical factors	CSR	Coefficient of variation	Odds ratio (95%CI)	P value
Day 1	Dexlansoprazole	Null	15.80%	-1.249 ± 0.543	0.285 (0.103-0.789)	0.022
	Esomeprazole	Female				
Day 3	Dexlansoprazole	Null	18.40%	-1.254 ± 0.519	0.287 (0.099-0.832)	0.016
	Esomeprazole	Female				
Day 7	Dexlansoprazole	Null				
	Esomeprazole	Null				

CSR: Complete symptom resolution; PPI: Proton pump inhibitor.

**Table 5** Multivariate analysis of the clinical factors predictive of complete symptom resolution within one week

Time	Clinical factor	CSR	Coefficient of variation	Odds ratio (95%CI)	P value
Day 1	Spicy food	No: 37.3% Yes: 21.4%	-0.969 ± 0.438	0.380 (0.161-0.896)	0.027
Day 3	Null				
Day 7	Null				

CSR: Complete symptom resolution.

enzyme system, mainly by CYP2C19 and CYP3A4<sup>[22,23]</sup>. In the pharmacokinetics report of esomeprazole<sup>[24]</sup>, the mean exposure (AUC) to esomeprazole increases from 4.32  $\mu\text{mol}\cdot\text{h}/\text{L}$  on day 1 to 11.2  $\mu\text{mol}\cdot\text{h}/\text{L}$  on day 5 after a 40-mg once-daily dose, indicating that the pharmacokinetics of esomeprazole are time- and dose-dependent<sup>[25]</sup>. For dexlansoprazole<sup>[26,27]</sup>, no accumulation of dexlansoprazole occurs after multiple once-daily doses of 60 mg, although the mean AUC and max concentration (C<sub>max</sub>) values of dexlansoprazole are slightly higher (less than 10%) on day 5 than on day 1. We validated this finding by calculating the C<sub>max</sub> of dexlansoprazole, which was 16  $\mu\text{mol}\cdot\text{h}/\text{L}$  on day 1 and 17.67  $\mu\text{mol}\cdot\text{h}/\text{L}$  on day 5. As a result, dexlansoprazole almost achieved the target concentration on day 1. Second, ample evidence has shown that estrogen and progestogen can enhance relaxation of the lower esophageal sphincters and induce GERD symptoms<sup>[28-30]</sup>, especially in postmenopausal women taking hormone replacement therapy (HRT)<sup>[31-36]</sup>. These hypotheses might explain why female patients taking esomeprazole needed at least 3 more days to accumulate a sufficient plasma concentration to achieve plateau levels and desirable clinical effects.

Another observation in this study was the lower CSR rates in patients with the habit of eating spicy foods in the esomeprazole group at day 1 after the multivariate analysis. No reliable data are available in the existing literature regarding the role of diet or specific foods or drinks in GERD<sup>[37]</sup>. Some foods are believed to induce or worsen GERD symptoms in daily clinical practice, and this belief has led to advising patients to avoid the suspect foods<sup>[38]</sup>. Nebel *et al.*<sup>[39]</sup> demonstrated that fried foods, spicy foods, and

alcohol were the most common precipitating factors of heartburn, but this study had no control group and did not quantify the intake of dietary items. In contrast, our study used a dietary questionnaire to estimate the frequency of the consumption of different types of food.

In addition to the above shortcoming, this study has other limitations. First, we enrolled only patients with Los Angeles grade A or B erosive esophagitis in this study and not those with Los Angeles grade C or D erosive esophagitis or Barrett's esophagus. As a result, the study may not represent the clinical effects of the entire GERD population. Second, this study used dietary questionnaires to estimate the frequency of consumption of different types of foods but did not quantify the fat or carbohydrate content. Nonetheless, this pilot study is the first important report to compare the clinical efficacy of a one-week dual delayed-release treatment with dexlansoprazole at 60 mg and esomeprazole at 40 mg for grades A and B GERD patients, since fast symptomatic relief is an important unmet need in the treatment of GERD.

In conclusion, the overall CSR rates for GERD were similar at days 1 through 7 for both the dexlansoprazole and esomeprazole groups, although a higher CSR was observed at day 3 in female patients who received a single dose of dexlansoprazole. Since rapid onset of proton-pump inhibitors for fast symptom relief is an unmet need for the treatment of GERD and no report have investigated the short-term clinical effects of dexlansoprazole 60 mg vs esomeprazole 40 mg, this finding of this pilot study is novel. Furthermore, these findings may have important implications for clinical practice when treating patients with grades A and B GERD. This issue was hampered by the small sample

size. Thus, we believe that large-scale comparative studies are necessary.

## ARTICLE HIGHLIGHTS

### Research background

Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder worldwide and continues to increase in incidence due to the aging population and obesity epidemic. Although proton pump inhibitors (PPIs) represent the mainstay of treatment for healing erosive esophagitis, symptom relief, and preventing complications, several studies have shown that up to 40% of GERD patients report either a partial or a complete lack of response of their symptoms after taking a standard once daily PPI dose. Rapid onset proton-pump inhibitors for fast symptom relief is an unmet need for GERD treatment. To date, no reports have investigated the short-term clinical effects and timing to symptom relief of gastroesophageal reflux disease (GERD) between dexlansoprazole (60 mg) and esomeprazole (40 mg). This report is the first randomized, controlled, open-label study to compare the 7-d clinical effects of single doses of dexlansoprazole at 60 mg and esomeprazole at 40 mg for LA grades A and B erosive esophagitis.

### Research motivation

A study comparing the pharmacokinetic effects of different PPIs 12-24 h post-dose showed that the mean percentage of time with a pH > 4 and the average of the pH mean were greater for dexlansoprazole than for esomeprazole (60% vs 42%,  $P < 0.001$  and pH 4.5 vs 3.5,  $P < 0.001$ ). However, this study did not report the clinical effects after the use of tablets. Therefore, the significance of solving these problems for future research in this field should be based on large-scale, head-to-head comparisons of these PPIs on immediate symptom relief for GERD to fulfill the unmet need in real-world treatment.

### Research objectives

The main objectives realized in this study motivated us to conduct this randomized, controlled, open-label study that compared the 7-d clinical effects of single doses of dexlansoprazole at 60 mg and esomeprazole at 40 mg for LA grades A and B erosive esophagitis.

### Research methods

This study was funded by the Research Foundation of the Chang Gung Memorial Hospital, Taiwan (CMRPG8D1441), and has been registered in a publicly accessible registry (ClinicalTrials.gov number: NCT03128736). We enrolled 175 adult GERD subjects and randomized them in a 1:1 ratio into two sequence groups that defined the order in which they received single doses of dexlansoprazole ( $n = 88$ ) and esomeprazole ( $n = 87$ ) for an ITT. Written informed consent was obtained from each patient. The patients were asked to complete the Chinese GERDQ upon recruitment. Blood samples were collected to measure the fasting blood sugar, serum cholesterol, and triglyceride levels. In addition, the BMI was calculated. A complete medical history and demographic data were obtained from each patient. The primary end points were the complete symptom resolution (CSR) rates at days 1, 3, and 7. CSR was defined as no reflux symptoms sufficient to impair the quality of life before the end of the initial treatment phase. The main outcome measures were the CSR rates at days 1, 3 and 7 of the initial treatment period. All patients starting esomeprazole or dexlansoprazole as their initial treatment were included in the ITT analysis. Patients with poor drug compliance were excluded from the PP analysis.

### Research results

Thirteen patients were lost during the follow up period, resulting in the inclusion of 81 patients in each group in the PP analysis. The CSRs for both groups were similar at days 1, 3 and 7. In the subgroup analysis, female patients achieved higher CSRs in the dexlansoprazole group than in the esomeprazole group at day 3 (38.3% vs 18.4%,  $P = 0.046$ ). An increasing trend toward CSR was observed at day 7 (55.3% vs 36.8%,  $P = 0.09$ ). In the esomeprazole group, female sex was a negative predictive factor for CSR at post-dose days 1 (OR = -1.249 ± 0.543; 95%CI: 0.287 (0.099-0.832),  $P = 0.022$ ) and 3 (OR = -1.254 ±

0.519; 95%CI: 0.285 (0.103-0.789),  $P = 0.016$ ). Patients with spicy food eating habits achieved lower CSRs on day 1 (37.3% vs 21.4%, OR = -0.969 ± 0.438; 95%CI: 0.380 (0.161-0.896),  $P = 0.027$ ).

### Research conclusions

The conclusion of this study was that the overall CSR rates for GERD were similar on days 1 through 7 for both the dexlansoprazole and esomeprazole groups, although a higher incidence was observed on day 3 in female patients who received a single dose of dexlansoprazole. The findings of this study are novel, since no report has investigated the short-term clinical effects of dexlansoprazole 60 mg vs esomeprazole 40 mg. This comparison represents an unmet need for GERD treatment in real-world clinical practice. The findings in this study could have important implications for clinical practice in the future for the treatment of grade A and B GERD patients. Furthermore, this study observed that female sex was a negative predictive factor for CSR at post-dose days 1 and 3 in the esomeprazole group. These findings implied that esomeprazole at 40 mg required more time (3 d) than dexlansoprazole at 60 mg to attain CSR in females. The new theories proposed suggest that these observations could be due to differences in the pharmacokinetics of esomeprazole and dexlansoprazole. Esomeprazole is time- and dose-dependent, especially at days 1 and 5. No accumulation of dexlansoprazole occurs after multiple once-daily doses at 60 mg. The authors validated this possibility by calculating the  $C_{max}$  of dexlansoprazole, which was 16  $\mu\text{mol}\cdot\text{h/L}$  on day 1 and 17.67  $\mu\text{mol}\cdot\text{h/L}$  on day 5. As a result, dexlansoprazole almost achieved the target concentration on day 1. In addition, there is ample evidence that estrogen and progesterone enhance relaxation of the lower esophageal sphincters and induce GERD symptoms, especially in post-menopausal women taking hormone replacement therapy. These hypotheses could explain why female patients taking esomeprazole needed at least 3 more days to accumulate a sufficient plasma concentration to achieve plateau levels and desirable clinical effects.

### Research perspectives

The important message of this study is that rapid onset PPIs for fast symptom relief remains an unmet need for GERD treatment. However, no report has investigated the short-term clinical effects of dexlansoprazole 60 mg vs esomeprazole 40 mg. Thus, the findings of this pilot study are novel and may have important implications for clinical practice in the future for the treatment of patients with grades A and B GERD. This pilot study was hampered by the small sample size. We believe that large-scale randomized controlled trials are necessary to further fulfill the future perspectives.

## REFERENCES

- 1 **El-Serag HB.** Time trends of gastroesophageal reflux disease: a systematic review. *Clin Gastroenterol Hepatol* 2007; **5**: 17-26 [PMID: 17142109 DOI: 10.1016/j.cgh.2006.09.016]
- 2 **El-Serag HB, Graham DY, Satia JA, Rabeneck L.** Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. *Am J Gastroenterol* 2005; **100**: 1243-1250 [PMID: 15929752 DOI: 10.1111/j.1572-0241.2005.41703.x]
- 3 **Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ.** Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 2012; **143**: 1179-1187.e1-3 [PMID: 22885331 DOI: 10.1053/j.gastro.2012.08.002]
- 4 **Modlin IM, Moss SF.** Symptom evaluation in gastroesophageal reflux disease. *J Clin Gastroenterol* 2008; **42**: 558-563 [PMID: 18364584 DOI: 10.1097/MCG.0b013e31816207cb]
- 5 **Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV;** American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology* 2008; **135**: 1383-1391, 1391.e1-1391.e5 [PMID: 18789939 DOI: 10.1053/j.gastro.2008.08.045]

- 6 **Hershovici T**, Fass R. An algorithm for diagnosis and treatment of refractory GERD. *Best Pract Res Clin Gastroenterol* 2010; **24**: 923-936 [PMID: 21126704 DOI: 10.1016/j.bpg.2010.10.004]
- 7 **Fass R**. Proton pump inhibitor failure--what are the therapeutic options? *Am J Gastroenterol* 2009; **104** Suppl 2: S33-S38 [PMID: 19262545 DOI: 10.1038/ajg.2009.50]
- 8 **Revicki DA**, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. *Am J Med* 1998; **104**: 252-258 [PMID: 9552088]
- 9 **Kukulka M**, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. *Clin Exp Gastroenterol* 2011; **4**: 213-220 [PMID: 22016582 DOI: 10.2147/CEG.S24063]
- 10 **Wong WM**, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, Xia HH, Huang JQ, Chan CK, Lam SK, Wong BC. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. *Aliment Pharmacol Ther* 2003; **18**: 595-604 [PMID: 12969086]
- 11 **Lundell LR**, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. *Gut* 1999; **45**: 172-180 [PMID: 10403727]
- 12 **Vakil N**, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006; **101**: 1900-1920; quiz 1943 [PMID: 16928254 DOI: 10.1111/j.1572-0241.2006.00630.x]
- 13 **Jones B**, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. *BMJ* 1996; **313**: 36-39 [PMID: 8664772]
- 14 **Katz PO**, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013; **108**: 308-328; quiz 329 [PMID: 23419381 DOI: 10.1038/ajg.2012.444]
- 15 **Metz DC**, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. *Aliment Pharmacol Ther* 2009; **29**: 742-754 [PMID: 19210298 DOI: 10.1111/j.1365-2036.2009.03954.x]
- 16 **Sharma P**, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. *Aliment Pharmacol Ther* 2009; **29**: 731-741 [PMID: 19183157 DOI: 10.1111/j.1365-2036.2009.03933.x]
- 17 **Richter JE**, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. *Am J Gastroenterol* 2001; **96**: 656-665 [PMID: 11280530 DOI: 10.1111/j.1572-0241.2001.3600\_b.x]
- 18 **Kahrilas PJ**, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. *Aliment Pharmacol Ther* 2000; **14**: 1249-1258 [PMID: 11012468]
- 19 **Schmitt C**, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. *Dig Dis Sci* 2006; **51**: 844-850 [PMID: 16642422 DOI: 10.1007/s10620-005-9062-4]
- 20 **Hsu PI**, Lu CL, Wu DC, Kuo CH, Kao SS, Chang CC, Tai WC, Lai KH, Chen WC, Wang HM, Cheng JS, Tsai TJ, Chuah SK. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis. *Clin Gastroenterol Hepatol* 2015; **13**: 859-66. e1 [PMID: 25245625 DOI: 10.1016/j.cgh.2014.09.033]
- 21 **Wu MS**, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2013; **38**: 190-201 [PMID: 23718547 DOI: 10.1111/apt.12349]
- 22 **Stedman CA**, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. *Aliment Pharmacol Ther* 2000; **14**: 963-978 [PMID: 10930890]
- 23 **Shin JM**, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. *J Neurogastroenterol Motil* 2013; **19**: 25-35 [PMID: 23350044 DOI: 10.5056/jnm.2013.19.1.25]
- 24 **Junghard O**, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. *Eur J Clin Pharmacol* 2002; **58**: 453-458 [PMID: 12389067 DOI: 10.1007/s00228-002-0502-1]
- 25 **Andersson T**, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. *Aliment Pharmacol Ther* 2001; **15**: 1563-1569 [PMID: 11563995]
- 26 **Metz DC**, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. *Aliment Pharmacol Ther* 2009; **29**: 928-937 [PMID: 19298580 DOI: 10.1111/j.1365-2036.2009.03984.x]
- 27 **Behm BW**, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. *Expert Rev Gastroenterol Hepatol* 2011; **5**: 439-445 [PMID: 21780890 DOI: 10.1586/egh.11.37]
- 28 **Smout AJPM**. Gastro-oesophageal reflux disease. Pathogenesis and Diagnosis. In *Evolving concepts in Gastrointestinal Motility*. Edited by Champion MC, Orr WC. Oxford, England: Blackwell Science; 1996: 46-63
- 29 **Van Thiel DH**, Gavaler JS, Stremple J. Lower esophageal sphincter pressure in women using sequential oral contraceptives. *Gastroenterology* 1976; **71**: 232-234 [PMID: 939383]
- 30 **Bruce LA**, Behsudi FM. Progesterone effects on three regional gastrointestinal tissues. *Life Sci* 1979; **25**: 729-734 [PMID: 491852]
- 31 **Menon S**, Prew S, Parkes G, Evans S, Smith L, Nightingale P, Trudgill N. Do differences in female sex hormone levels contribute to gastro-oesophageal reflux disease? *Eur J Gastroenterol Hepatol* 2013; **25**: 772-777 [PMID: 23470358 DOI: 10.1097/MEG.0b013e32835fbaab]
- 32 **Nordenstedt H**, Zheng Z, Cameron AJ, Ye W, Pedersen NL, Lagergren J. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. *Gastroenterology* 2008; **134**: 921-928 [PMID: 18294635 DOI: 10.1053/j.gastro.2008.01.009]
- 33 **Zheng Z**, Margolis KL, Liu S, Tinker LF, Ye W; Women's Health Initiative Investigators. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. *Gastroenterology* 2008; **135**: 72-81 [PMID: 18502208 DOI: 10.1053/j.gastro.2008.03.039]
- 34 **Jacobson BC**, Moy B, Colditz GA, Fuchs CS. Postmenopausal hormone use and symptoms of gastroesophageal reflux. *Arch Intern Med* 2008; **168**: 1798-1804 [PMID: 18779468 DOI: 10.1001/archinte.168.16.1798]
- 35 **Alvarez-Sánchez A**, Rey E, Achem SR, Díaz-Rubio M. Does progesterone fluctuation across the menstrual cycle predispose to gastroesophageal reflux? *Am J Gastroenterol* 1999; **94**: 1468-1471 [PMID: 10364009 DOI: 10.1111/j.1572-0241.1999.01128.x]
- 36 **Close H**, Mason JM, Wilson D, Hungin AP. Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study. *BMC Gastroenterol* 2012; **12**: 56 [PMID:

22642788 DOI: 10.1186/1471-230X-12-56]

- 37 **Festi D**, Scaioi E, Baldi F, Vestito A, Pasqui F, Di Biase AR, Colecchia A. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. *World J Gastroenterol* 2009; **15**: 1690-1701 [PMID: 19360912 DOI: 10.3748/wjg.15.1690]
- 38 **DeVault KR**, Castell DO; American College of Gastroenterology.

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol* 2005; **100**: 190-200 [PMID: 15654800 DOI: 10.1111/j.1572-0241.2005.41217.x]

- 39 **Nebel OT**, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. *Am J Dig Dis* 1976; **21**: 953-956 [PMID: 984016]

**P- Reviewer:** Cicala M, Skrypnyk IN, Thomopoulos KC  
**S- Editor:** Ma YJ **L- Editor:** Ma JY **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

